Transcript for Is supply drop of Johnson & Johnson vaccine major setback for vaccination plan?
this from Dr. Paul offit, a member of the fda's advisory panel and the director of the vaccine education center at the children's hospital of Philadelphia. Dr. Offit, good morning. Let's start with these problems with the j&j vaccine. With the supply dropping all of a sudden, do you think that's a major setback for the progress toward getting everybody vaccinated? I don't think so. I think we're leaning right now on the two mrna vaccines, pfizer and modern. Between them we should still be able to have enough vaccines for everybody who would benefit from it hopefully by the summer. That is good news. What, though, about these unusual symptoms, some people say they've been experiencing after getting the j&j vaccine. Are those of concern to you? Not really. I think what's happened actually in a few of those sites is people got anxious so they started to hyperventilate. They had tingling in their hands and feet and they felt nauseated, sometimes vomited. When you see one person do that at a site that makes you more anxious. That's what happened at a few sites but the sites are back up and running again. I think that's all it was. Anxiety can certainly be contagious. One more question about the ask j&j vaccine. The European union's drug regulator is reviewing reports of rare blood clots in four people who received j&j's covid-19 vaccine. Do you think this could have implications for the use of the vaccine in this country? I think we certainly need to look closely at that. Certainly the uk astrazeneca vaccine which is a so-called replication-defective adenovirus is at some level similar to the j&j vaccine which is a replication-defective human adenovirus. It would be a very rare side effect here, a side effect for the astrazeneca vaccine that was occurring 1 per 400,000 people. We'll see whether or not that's a problem but the important thing is to look and I think the CDC and food and drug administration need to look at very carefully when people get that to make sure that those blood clots are not a consequence of that. Something to keep our eye on here. Meanwhile, pfizer is now asking the fda to authorize its vaccine for 12-year-olds to 15-year-olds. I know you're on the fda advisory panel that will offer a recommendation. Do you have any concerns at least preliminarily about this request? First of all, I'm not sure that comes from our committee, the advisory committee. The top line data look very good. It was a study of about 2,200 children that did or didn't get that vaccine. There were 18 cases of covid-19 all in the placebo group. The vaccine appeared to be safe plus frankly you wouldn't expect there to be much of a difference in the 12 to 15-year-old as compared to 16 to 18-year-old for whom that vaccine is already approved so I'm optimistic that the top line data are exactly what they appear to be, and we need vaccines for children because children can certainly be hurt by this virus. Dr. Offit, thank you very much. Always great to see you on a Saturday morning, thank you. Thank you.
This transcript has been automatically generated and may not be 100% accurate.